Foamix Pharmaceuticals Ltd.: 10-Q filed 2018-05-08
What Foamix Pharmaceuticals Ltd. reported in its quarterly report filed 2018-05-08 (fiscal Q1 2018): 27 published measures, 54 facts as tagged in accession 0001178913-18-001521.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2018-05-08
- Fiscal period
- fiscal Q1 2018
- Accession
- 0001178913-18-001521 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Foamix Pharmaceuticals Ltd. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 56,469,000 | USD | |
| At 2017-12-31 | 80,254,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 12,125,000 | USD | |
| At 2017-12-31 | 11,653,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 44,344,000 | USD | |
| At 2017-12-31 | 68,601,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 12,770,000 | USD | |
| At 2017-12-31 | 15,956,000 | USD | |
| At 2017-03-31 | 26,157,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | -25,977,000 | USD | 90 |
| 2017-01-01 to 2017-03-31 | -14,384,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | -23,193,000 | USD | 90 |
| 2017-01-01 to 2017-03-31 | -12,053,000 | USD | 90 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 122,000 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 280,000 | USD | 90 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 906,000 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 927,000 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 129,000 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 20,008,000 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 6,873,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | -167,223,000 | USD | |
| At 2017-12-31 | -141,281,000 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 330,000 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 71,000 | USD | 90 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 2,045,000 | USD | |
| At 2017-12-31 | 2,042,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 1,754,000 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 766,000 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | -25,720,000 | USD | 90 |
| 2017-01-01 to 2017-03-31 | -14,570,000 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 49,197,000 | USD | |
| At 2017-12-31 | 69,504,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 10,833,000 | USD | |
| At 2017-12-31 | 10,228,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 846,000 | USD | |
| At 2017-12-31 | 996,000 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 3,801,000 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 2,822,000 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 22,825,000 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 12,675,000 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 37,551,511 | shares | |
| At 2017-12-31 | 37,498,128 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 210,116,000 | USD | |
| At 2017-12-31 | 208,364,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | -127,000 | USD | |
| At 2017-12-31 | -58,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-03-31 | 32,000 | USD | |
| At 2017-12-31 | 32,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | -25,647,000 | USD | 90 |
| 2017-01-01 to 2017-03-31 | -14,313,000 | USD | 90 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | -26,011,000 | USD | 90 |
| 2017-01-01 to 2017-03-31 | -14,343,000 | USD | 90 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-03-31 | 86,000 | USD | 90 |
| 2017-01-01 to 2017-03-31 | 44,000 | USD | 90 |
Inspect the source
- Entity
- Foamix Pharmaceuticals Ltd. / CIK 0001606645
- Captured
- SEC response SHA-256
b102c73a58c0072ed43450ed763cdf19a044a1d9e904bd75734fe9a636bd7360
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001606645.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))